We are analyzing https://link.springer.com/article/10.1007/s10549-007-9756-8.

Title:
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients | Breast Cancer Research and Treatment
Description:
We analysed the clinical features, distribution of basal markers, prevalence of oncogene amplification, and outcome of triple negative (TN) compared to those of non-TN cancers in a series of adjuvant-anthracycline treated breast cancer patients. We examined the prognostic impact of the TN and BL phenotype in 245 breast cancer patients uniformly treated with adjuvant anthracycline-based chemotherapy following primary surgery, with regards to local relapse-free (LRFS), metastasis free (MFS), and breast cancer specific survival (BCSS). A comparative analysis of the clinicopathological characteristics, expression of basal markers (cytokeratins (Cks) 5/6, 14, 17, EGFR, and caveolin 1 and 2), MIB-1, p53 and topoisomerase II alpha, and prevalence of CCND1, MYC and TOP2A amplification in TN and non-TN breast tumours was performed. TN cancers were significantly associated with the expression of basal markers (all P < 0.0001). However 19.4% of TN tumours were negative for basal markers, whilst 7.3% of non-TN tumours expressed basal markers. TN phenotype was significantly associated with p53, MIB-1 and topoisomerase II alpha (all, P < 0.01) expression. No TN cancer harboured amplification of CCND1 or TOP2A. In univariate analysis, TN and BL phenotype were significantly associated with shorter MFS (both, P < 0.01) and BCSS (both, P < 0.005) but not LRFS. Despite treatment with standard dose anthracycline-based chemotherapy, the clinical outcome of TN and BL cancers remains poor. Alternative chemotherapeutic regimens and/or novel therapeutic approaches are warranted. Although a significant phenotypic overlap exists between TN and basal-like tumours, the TN phenotype is not an ideal surrogate marker for basal-like breast cancers.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

breast, cancer, article, pubmed, google, scholar, cas, res, expression, clin, molecular, amplification, analysis, reisfilho, markers, basallike, gene, pathol, negative, basal, cancers, phenotype, oncol, research, adjuvant, patients, study, clinical, triple, chemotherapy, triplenegative, immunohistochemical, prognostic, jones, tumours, access, invasive, tumor, carcinoma, carcinomas, treat, situ, privacy, cookies, content, data, treatment, savage, dowsett, topoisomerase,

Topics {✒️}

adjuvant anthracycline-treated patients month download article/chapter adjuvant anthracycline-based chemotherapy rodriguez-pinilla sm mammary myoepithelial cell–cinderella triple-negative breast cancers triple-negative breast cancer newly diagnosed african-american called triple-negative phenotype brca1-related breast carcinoma gene-expression-based predictors breast cancer staging reis-filho js single-institution compilation compared full article pdf early breast cancer 2/neu-amplified breast cancer triple negative paradox tissue microarrays access topoisomerase ii alpha related subjects breakthrough breast cancer privacy choices/manage cookies invasive breast cancer invasive breast carcinoma breast cancer subtypes operable breast cancer metaplastic breast carcinomas human breast cancer breast tumor subtypes predict high levels hereditary breast cancer familial breast cancer tissue-based detection population-based cohort cancer research london pathological prognostic factors long-term survival selectively inhibits growth breast tumor size cyclin d1 expression population-based study estrogen receptor negative breast cancer classification california cancer registry tumour breast carcinoma characteristics human breast tumours malignant breast tissue gene expression profiles

Questions {❓}

Bidard FC, Conforti R, Boulet T et al (2007) Does triple-negative phenotype accurately identify basal-like tumour?
Lakhani SR, O’Hare MJ (2001) The mammary myoepithelial cell–Cinderella or ugly sister?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
         description:We analysed the clinical features, distribution of basal markers, prevalence of oncogene amplification, and outcome of triple negative (TN) compared to those of non-TN cancers in a series of adjuvant-anthracycline treated breast cancer patients. We examined the prognostic impact of the TN and BL phenotype in 245 breast cancer patients uniformly treated with adjuvant anthracycline-based chemotherapy following primary surgery, with regards to local relapse-free (LRFS), metastasis free (MFS), and breast cancer specific survival (BCSS). A comparative analysis of the clinicopathological characteristics, expression of basal markers (cytokeratins (Cks) 5/6, 14, 17, EGFR, and caveolin 1 and 2), MIB-1, p53 and topoisomerase II alpha, and prevalence of CCND1, MYC and TOP2A amplification in TN and non-TN breast tumours was performed. TN cancers were significantly associated with the expression of basal markers (all P < 0.0001). However 19.4% of TN tumours were negative for basal markers, whilst 7.3% of non-TN tumours expressed basal markers. TN phenotype was significantly associated with p53, MIB-1 and topoisomerase II alpha (all, P < 0.01) expression. No TN cancer harboured amplification of CCND1 or TOP2A. In univariate analysis, TN and BL phenotype were significantly associated with shorter MFS (both, P < 0.01) and BCSS (both, P < 0.005) but not LRFS. Despite treatment with standard dose anthracycline-based chemotherapy, the clinical outcome of TN and BL cancers remains poor. Alternative chemotherapeutic regimens and/or novel therapeutic approaches are warranted. Although a significant phenotypic overlap exists between TN and basal-like tumours, the TN phenotype is not an ideal surrogate marker for basal-like breast cancers.
         datePublished:2007-10-06T00:00:00Z
         dateModified:2007-10-06T00:00:00Z
         pageStart:27
         pageEnd:44
         sameAs:https://doi.org/10.1007/s10549-007-9756-8
         keywords:
            Basal-like breast cancer
            Immunohistochemistry
            Chromogenic in situ hybridisation
            Prognosis, Tissue microarrays
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-007-9756-8/MediaObjects/10549_2007_9756_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-007-9756-8/MediaObjects/10549_2007_9756_Fig2_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:111
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:David S. P. Tan
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Caterina Marchió
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robin L. Jones
               affiliation:
                     name:The Royal Marsden Hospital Trust and Institute of Cancer Research London
                     address:
                        name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
                        type:PostalAddress
                     type:Organization
                     name:The Royal Marsden Hospital Trust
                     address:
                        name:Department of Academic Biochemistry, The Royal Marsden Hospital Trust, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kay Savage
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ian E. Smith
               affiliation:
                     name:The Royal Marsden Hospital Trust and Institute of Cancer Research London
                     address:
                        name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mitch Dowsett
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                        type:PostalAddress
                     type:Organization
                     name:The Royal Marsden Hospital Trust and Institute of Cancer Research London
                     address:
                        name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
                        type:PostalAddress
                     type:Organization
                     name:The Royal Marsden Hospital Trust
                     address:
                        name:Department of Academic Biochemistry, The Royal Marsden Hospital Trust, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jorge S. Reis-Filho
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
      description:We analysed the clinical features, distribution of basal markers, prevalence of oncogene amplification, and outcome of triple negative (TN) compared to those of non-TN cancers in a series of adjuvant-anthracycline treated breast cancer patients. We examined the prognostic impact of the TN and BL phenotype in 245 breast cancer patients uniformly treated with adjuvant anthracycline-based chemotherapy following primary surgery, with regards to local relapse-free (LRFS), metastasis free (MFS), and breast cancer specific survival (BCSS). A comparative analysis of the clinicopathological characteristics, expression of basal markers (cytokeratins (Cks) 5/6, 14, 17, EGFR, and caveolin 1 and 2), MIB-1, p53 and topoisomerase II alpha, and prevalence of CCND1, MYC and TOP2A amplification in TN and non-TN breast tumours was performed. TN cancers were significantly associated with the expression of basal markers (all P < 0.0001). However 19.4% of TN tumours were negative for basal markers, whilst 7.3% of non-TN tumours expressed basal markers. TN phenotype was significantly associated with p53, MIB-1 and topoisomerase II alpha (all, P < 0.01) expression. No TN cancer harboured amplification of CCND1 or TOP2A. In univariate analysis, TN and BL phenotype were significantly associated with shorter MFS (both, P < 0.01) and BCSS (both, P < 0.005) but not LRFS. Despite treatment with standard dose anthracycline-based chemotherapy, the clinical outcome of TN and BL cancers remains poor. Alternative chemotherapeutic regimens and/or novel therapeutic approaches are warranted. Although a significant phenotypic overlap exists between TN and basal-like tumours, the TN phenotype is not an ideal surrogate marker for basal-like breast cancers.
      datePublished:2007-10-06T00:00:00Z
      dateModified:2007-10-06T00:00:00Z
      pageStart:27
      pageEnd:44
      sameAs:https://doi.org/10.1007/s10549-007-9756-8
      keywords:
         Basal-like breast cancer
         Immunohistochemistry
         Chromogenic in situ hybridisation
         Prognosis, Tissue microarrays
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-007-9756-8/MediaObjects/10549_2007_9756_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-007-9756-8/MediaObjects/10549_2007_9756_Fig2_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:111
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:David S. P. Tan
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Caterina Marchió
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robin L. Jones
            affiliation:
                  name:The Royal Marsden Hospital Trust and Institute of Cancer Research London
                  address:
                     name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
                     type:PostalAddress
                  type:Organization
                  name:The Royal Marsden Hospital Trust
                  address:
                     name:Department of Academic Biochemistry, The Royal Marsden Hospital Trust, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kay Savage
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ian E. Smith
            affiliation:
                  name:The Royal Marsden Hospital Trust and Institute of Cancer Research London
                  address:
                     name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mitch Dowsett
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                     type:PostalAddress
                  type:Organization
                  name:The Royal Marsden Hospital Trust and Institute of Cancer Research London
                  address:
                     name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
                     type:PostalAddress
                  type:Organization
                  name:The Royal Marsden Hospital Trust
                  address:
                     name:Department of Academic Biochemistry, The Royal Marsden Hospital Trust, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jorge S. Reis-Filho
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:111
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Institute of Cancer Research
      address:
         name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
         type:PostalAddress
      name:The Royal Marsden Hospital Trust and Institute of Cancer Research London
      address:
         name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
         type:PostalAddress
      name:The Royal Marsden Hospital Trust
      address:
         name:Department of Academic Biochemistry, The Royal Marsden Hospital Trust, London, UK
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
         type:PostalAddress
      name:The Royal Marsden Hospital Trust and Institute of Cancer Research London
      address:
         name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
         type:PostalAddress
      name:The Royal Marsden Hospital Trust and Institute of Cancer Research London
      address:
         name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
         type:PostalAddress
      name:The Royal Marsden Hospital Trust
      address:
         name:Department of Academic Biochemistry, The Royal Marsden Hospital Trust, London, UK
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:David S. P. Tan
      affiliation:
            name:Institute of Cancer Research
            address:
               name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
               type:PostalAddress
            type:Organization
      name:Caterina Marchió
      affiliation:
            name:Institute of Cancer Research
            address:
               name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
               type:PostalAddress
            type:Organization
      name:Robin L. Jones
      affiliation:
            name:The Royal Marsden Hospital Trust and Institute of Cancer Research London
            address:
               name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
               type:PostalAddress
            type:Organization
            name:The Royal Marsden Hospital Trust
            address:
               name:Department of Academic Biochemistry, The Royal Marsden Hospital Trust, London, UK
               type:PostalAddress
            type:Organization
      name:Kay Savage
      affiliation:
            name:Institute of Cancer Research
            address:
               name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
               type:PostalAddress
            type:Organization
      name:Ian E. Smith
      affiliation:
            name:The Royal Marsden Hospital Trust and Institute of Cancer Research London
            address:
               name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
               type:PostalAddress
            type:Organization
      name:Mitch Dowsett
      affiliation:
            name:Institute of Cancer Research
            address:
               name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
               type:PostalAddress
            type:Organization
            name:The Royal Marsden Hospital Trust and Institute of Cancer Research London
            address:
               name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
               type:PostalAddress
            type:Organization
            name:The Royal Marsden Hospital Trust
            address:
               name:Department of Academic Biochemistry, The Royal Marsden Hospital Trust, London, UK
               type:PostalAddress
            type:Organization
      name:Jorge S. Reis-Filho
      affiliation:
            name:Institute of Cancer Research
            address:
               name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
      name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
      name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
      name:Department of Academic Biochemistry, The Royal Marsden Hospital Trust, London, UK
      name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
      name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
      name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
      name:Breast Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research London, London, UK
      name:Department of Academic Biochemistry, The Royal Marsden Hospital Trust, London, UK
      name:The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(180)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

6.21s.

LINK . SPRINGER . COM {}